


Interprofessional Insights:
Advanced Care Coordination for Patients with
Head and Neck Cancer

Jennifer Lewellyn, RN, OCN
Head and Neck Nurse Navigator

Jaclyn V. Moore, MS, RD, C.S.O.
Oncology Dietitian

Transforming Oncology Care Through Medically Integrated Collaboration




1


How to Claim Your CE Credit

For CE credit, please visit:
<https://www.lecturepanda.com/r/2025NCODASpringForum>

- Credit requirements must be completed within 60 days of the program activity date.
- Upon completion, credit will be transmitted electronically to ACPE.
- All transmitted credit will be viewable in your CPE Monitor profile within 24 hours.
- CE codes will be displayed at the end of the presentation and will not be redistributed after this presentation.



Transforming Oncology Care Through Medically Integrated Collaboration



2

DISCLOSURES


The following relevant financial relationships from the past 24 months have been identified and disclosed for the following faculty of this CE activity:

- Jaclyn V. Moore, MS, RD, C.S.O.
 - Speaker for Alcresta Therapeutics and AbbVie Pharmaceuticals.

No relevant financial relationships from the past 24 months have been identified for the following planners of this CE activity:

- Jennifer Lewellyn, RN, OCN
- Mary Anderson, BSN, RN, OCN

Transforming Oncology Care Through Medically Integrated Collaboration



3

OBJECTIVES

1. Describe the importance of interprofessional collaboration in head and neck oncology care

2. Analyze the impact prehabilitation, symptom management, and post-operative support can have on clinical outcomes

3. Identify the unique challenges faced by head and neck cancer patients in different geographical settings

4. Examine the long-term effects faced by head and neck cancer patients and strategies to support them into survivorship and beyond

Transforming Oncology Care Through Medically Integrated Collaboration

2024 NCODA
SPRING
FORUM

4

QUESTION #1

How often are you taking care of head and neck cancer patients?

a. Daily

b. Monthly

c. Infrequently

d. Never

Transforming Oncology Care Through Medically Integrated Collaboration

2024 NCODA
SPRING
FORUM

5

QUESTION #2

Where is your practice located?

a. Rural Healthcare Setting

b. Urban Healthcare Setting

c. Suburban Healthcare Setting


d. Metropolitan Healthcare Setting

Transforming Oncology Care Through Medically Integrated Collaboration

2024 NCODA
SPRING
FORUM

6

What is Head and Neck Cancer?



Source: <https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet>



7

Stages of Head and Neck Cancer

Stage 0 (Cancer in Situ)

Tumor only in one spot. No cancer cells in deeper tissue, nearby lymph nodes, or distal sites.

Stage 1


Primary tumor is 2cm or smaller with no other detectable cancer cells in other areas

Stage 2

Primary tumor is 2-4cm across and no other detectable cancer cells in other areas

Stage 3

Primary tumor is greater than 4cm across or any size, but has one positive lymph node on the same size as the primary tumor



<https://www.cancer.gov/types/head-and-neck/Classification-and-Stage-of-Head-and-Neck-Cancer>




8

Stages of Head and Neck Cancer Cont..

Stage 4A

Primary tumor can be any size, but is growing into nearby structures and either:

- There is one lymph node on the same side that is 3-6cm across
- Cancer cells are present in one lymph node on the opposite side and less than 6cm across
- Cancer cells are present in 2 or more lymph nodes, but all are smaller than 6cm



www.entnet.org/academy/

Stage 4B

Primary tumor has invaded deeper tissue or it has spread to one or more lymph nodes and are larger than 6cm across, but has not spread to distant sites.

Stage 4C

Cancer cells have spread to distant sites



9


Diagnosis and Treatment Options

Diagnostics / Staging

- CT Head/Neck and Chest
- PET
- Biopsy

Treatment Options


- Chemotherapy (induction, curative intent, palliative intent)
- Radiation therapy
- Concurrent Chemoradiation therapy
- Surgery (resection, reconstruction)
- Immunotherapy
- Targeted therapy




10

Head and Neck Multidisciplinary Team

<p>Primary H&N physician team</p> <ul style="list-style-type: none">• Medical Oncologist• Radiation Oncologist• Ear, Nose and Throat Specialist (ENT)• Head and Neck Surgeon/Otolaryngologist• Dentist/Oral Surgeon	<p>Additional H&N team members</p> <ul style="list-style-type: none">• Interventional Radiologist (IR)/Surgeon• Plastic Surgeon• Respiratory Therapist (RT)• Occupational Therapist(OT)/Lymphedema (LT)• Home Infusion Pharmacy/DME Company• Treatment Nurse (Tx Nurse)• Palliative Care/ Pain Management• Wound Care• Home Health/ Skilled Nursing• Behavioral Oncology• Patient Financial Advocate (PFA)• Audiologist• Primary Care Physician (PCP)• Smoking/Alcohol Cessation Counselors
<p>Primary H&N support team</p> <ul style="list-style-type: none">• Nurse Navigator (RN)• Speech Language Pathologist (SLP)• Registered Dietitian (RD)• Physical Therapist (PT)• Licensed Clinical Social Worker (LCSW)• Clinical Pharmacist	




11



12

Primary Head and Neck Physician Team


- **Medical Oncologist**
 - Meets the patient at diagnosis to discuss induction vs primary vs adjuvant systemic treatment options
- **Radiation Oncologist**
 - Meets the patient at diagnosis to discuss primary vs adjuvant options
 - Assesses oral cavity and determines need for dental eval/extractions
- **Ear, Nose and Throat Specialist (ENT)**
 - May provide initial diagnosis and/or surveillance
- **Head and Neck Surgeon/Otolaryngologist**
 - Meets the patient at diagnosis to discuss primary vs palliative resection
 - May assume the role of ENT for ongoing evaluation and surveillance
- **Dentist/Oral Surgeon**
 - Removes damaged or at-risk teeth prior to radiation treatment
 - Provides fluoride trays and long-term oral care recommendations




13

Additional Head and Neck Team Members

- **Interventional Radiologist (IR)/Surgeon**
 - Places gastrostomy tube for temporary nutrition access
 - Places implanted port for systemic therapy
 - May perform biopsy
- **Plastic Surgeon**
 - Participates in reconstruction following oncologic resection
 - May perform cosmetic surgery well after initial treatment
- **Occupational Therapist (OT)/Lymphedema Therapist (LT)**
 - Introduced to patient at the beginning of treatment
 - Follows patient during and after treatment for lymphedema therapy and long term eval of ADLs
- **Home Infusion Pharmacy/DME Company**
 - Provides necessary enteral nutrition and medical supplies



Stock photo



14

At Diagnosis – What to Expect

- ENT
- Referrals to Oncology
 - Surgery
 - Medical oncology
 - Radiation oncology
 - Dentist
- New Patient consult appointments
 - Diagnosis and treatment recs
 - Imaging ordered: CT, PET
 - Biopsy






Photo: Diagnosis and treatment of ENT disease.
<https://stock.adobe.com/stock-photo/stock-photo/20442757634>, downloaded on March 13, 2025.



15

Case Study #1: Surgical Patient

52 y/o male, L tonsil SCC, -P16
PMHx: vertigo, smoker, homeless
Ht: 66", Wt: 132#



STOCK PHOTO

6/14/24

ED: L tongue pain

1/22/25

No showed to PET scan

1/29/25


H&N surgery eval/
Multidisciplinary Clinic
(MDC)

1/13/25

ED: L cheek pain x 6 months
and L neck
lymphadenopathy

1/27/25

Return ED worse pain




16

Case Study #1: Initial Visit / Pre-operative Course

1/29/25: H&N MDC Visit

- H&N Surgery – pt not tolerating any PO, pain uncontrolled, social/transportation issues. Decision made to direct admit for prophylactic G tube, prehabilitation, and surgery.
- Radiation Oncology – introduction, plans to f/u after operation.
- H&N RN Navigator – introduction, review of treatment course, H&N MDC team and contacts, plans to f/u inpt.
- SLP – initial bedside eval, plans to f/u inpt.

1/29/25: Direct admission from H&N MDC (pedway).





17

Case Study #1: Initial Visit / Pre-operative Course


Patient presented to H&N MDC Clinic 1/29/2025

- H&N Surgery
 - Not tolerating anything by mouth
 - Uncontrolled Pain
 - Social and Transportation issues.
 - Decision made to direct admit for prophylactic G tube, prehabilitation, and surgery.
- Radiation Oncology
 - Introduction to services and treatment
 - Discussed Plans to f/u after operation
- H&N RN Navigator
 - Introduction
 - Provides information on H&N MDC team and how to contact
 - Reviews treatment plan and next steps
 - Plans to f/u inpatient
- SLP
 - Initial bedside evaluation
 - Plans to f/u inpatient


 Direct admission to hospital from the MDC via pedway




18




19




20




21



22



23




24

Case Study #1 Surgical Pt Summary

Navigation Takeaways

- Delayed diagnosis, multiple ED visits without adequate f/u
- H&N MDC team efforts made to keep patient in-house from first MDC appointment vs lost to follow-up
- Free flap surgery with aggressive prehab and rehab support
- Prompt adjuvant tx
- Multiple resources leveraged including care coordination, financial support, transportation, lodging, medication access, nutrition, SLP services, PT
- Interprofessional collaboration is essential in H&N cancer management and key to successful patient outcomes




25

QUESTION #3

Which of the following is not a late stage effect related to head and neck cancer treatment?

- a. Lymphedema
- b. Mucositis
- c. Xerostomia
- d. Trismus




Transforming Oncology Care Through Medically Integrated Collaboration

26

Case Study #2 Concurrent Chemoradiation (CCRT)

65 y/o male, Oropharyngeal Cancer
PMHx: HTN, CAD, GERD, CABG
Distant history of smoking for 15yrs, quit 15 yrs ago. ETOH use



7/5/24

Reports 6-month hx fullness, soreness, and bleeding of L throat
PCP place ENT referral

7/23/24


ENT visualizes 3cm 1B mass and 2cm level 2 mass on R side
Ref to Med Onc

7/16/24

CT shows L oropharynx/tongue base mass. Enlarged LN

8/1/24


US guided FNA by IR




27

Case Study #2: CCRT continued

- Diagnosis: oropharyngeal cancer 8/2/24
 - Core biopsy of L cervical level 2 LN
 - Reviewed by pathologist
 - SCC, P16+
 - Staging: cT2N1
- Recommended treatment:
 - Radiation 70 Gy in 35 fx
 - IMRT
 - Chemo weekly
 - Cisplatin
- Dental evaluation and treatment prior to start of Tx coordinated by nurse navigator




Yam SS, et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology NRG03). JCO 39, 956-965(2021) doi: 10.1200/JCO.2019.8388




28

Case Study #2: CCRT continued

- Phases of Treatment:
 - First day CCRT
 - Weekly labs (CBC, CMP, Mag), recheck, OTV (on treatment visit)
- Symptom Management
 - Radiation: radiodermatitis, dysphagia, odynophagia, fatigue, lymphedema
 - Chemo: N/V, neuropathy, tinnitus
 - Psychological/emotional distress
- Follow up: 1 month, 3-month, PET
 - Radiation Oncology
 - Medical Oncology
 - ENT repeat bx 1/10/25: negative




Stock photo



29

Case Study #2: CCRT continued




The timeline shows the progression of treatment from July 5, 2024, to January 22, 2025. Key events include diagnosis, staging, treatment planning, and the start of radiation and chemotherapy. The timeline is divided into two rows of events, with dates marked by circles and connected to the event descriptions by lines.

30

Case #2: CCRT Survivorship

- Survivorship planning (within 1 yr) and evaluation for long term side effects that impact quality of life.
- Ongoing assessments for psychological distress
- Long term surveillance: consider tumor site, stage, prognostic factors, symptoms and changes based on clinical exam
- Radiation: Clinical evaluations with scope
 - Lymphedema, Fibrosis
 - Dysphagia, Dysgeusia, Trismus
 - Hypothyroid
 - Carotid Artery
 - Dental evaluation and follow up
- Medical Oncology/Cisplatin: Clinical evaluations
 - Audiology test
 - Lab work, renal function



31

NCCN Guidelines for P16 HPV+ Oropharynx Cancer


Concurrent systemic therapy and XRT is the primary treatment for **T2 N1 M0** disease.

Primary therapy for high-risk

- Weekly Cisplatin 40mg/m2
- Concurrent XRT 66-70 Gy Monday - Friday over 6-7 weeks
- IMRT preferred to minimize dose to critical structures

*P16 is a cyclin-dependent kinase inhibitor that blocks cell cycle progression at G1 to S check point. Associated with HPV infection.


Stephen S et al. Significance of p16 in site-specific HPV positive and HPV negative HNSCC. doi:10.5583/ncov2021u53



32

NCCN Guidelines: Follow-Up Recommendations Post Systemic Therapy/RT


- Clinical assessment 4-8 weeks after TX completion
- CT with contrast of primary and neck in 8-12 weeks
- Head and neck exam with mirror and fiberoptic exam every
 - 1-3 months on year 1
 - 2-4 months on year 2
 - 4-8 months on years 3-5
 - Annually after year 5
- TSH every 6-12 months if neck irradiation
- Ongoing SLP, PT, and nutritional assessment until stable
- Dental evaluation and lymphedema management as indicated
- Ongoing surveillance for depression
- Survivorship care planning within one year



33

Case Study #2: CCRT Summary

- Time from diagnosis to evaluate effectiveness of treatment: 5+ mos
- Medical Providers involved: 7
- Supportive staff: Nurse, radiation therapists, clinical staff, social worker, dietitian, SLP, RN Navigator
- Complex psychosocial challenges (depression, substance abuse, body image disturbance, broken support systems, social isolation)
- Survivorship plan and continued surveillance for 5 years
- Possibility of osteoradionecrosis or residual malignancy




34


Long-Term Side Effects

- Dysphagia
- Dysgeusia
- Trismus
- Lymphedema
- Hypothyroid
- Carotid
- Trauma

DYSPHAGIA



Stock Photo



35

QUESTION #4

What percentage of patients with locally advanced squamous cell carcinoma head and neck cancer will reoccur?


a. 25%

b. 33%


c. 50%

d. 75%

Transforming Oncology Care Through Medically Integrated Collaboration



36




Stock photo

Case Study #3: Recurrent H&N Cancer

71 y/o male, recurrent R vocal cord SCC, -P16
PMHx: Smoker, GERD, HTN, OSA, Appendectomy.
Cancer Hx: prostate cancer s/p XRT (2021), colorectal cancer s/p colectomy (2022), R vocal cord squamous cell carcinoma s/p definitive XRT (2023), L forehead/back basal cell carcinoma s/p wide local excision (11/2024).
Ht: 67", Wt: 190#

Presentation:
1/27/25: Referred to H&N MDC 2/2 persistent sore throat and hoarseness. Prior oncology care at OSH.
1/27/25: Direct laryngoscopy endoscopy with biopsy



37

Case Study #3: Initial Visit / Pre-operative Course


2/5/25: Pt canceled CT scans and MDC visit due to acute illness

2/14/25: CT head, neck, and chest performed (recurrent larynx SCC, cervical lymph nodes, no distant mets)

2/19/25: Pt canceled MDC visit due to weather/transportation

2/21/25: Initial H&N MDC Visit

- H&N Surgery – recommended TL, b/l ND, L/R forearm FF
- Radiation Oncology – discouraged re-irradiation 2/2 risk for non-functional larynx
- H&N RN Navigator – follow-up, review of treatment course, H&N MDC team and contacts, plans to f/u inpt
- SLP – initial bedside eval, plans to f/u inpt
- RD – initial eval, prehab



38


Case Study #3: Hospital Course

Admitted for salvage oncologic resection s/p total laryngectomy, b/l ND, L thigh FF, NGT

D/C home with enteral feeds. Remains NPO.

3/3/25 3/4/25 3/12/25

Start Impact Peptide 1.5 @ 110/hr continuous NPO




39

Case Study #3: Pathology Result

- 2.6 cm primary tumor. Transglottic extension present.
- Tumor laterality: right; left: midline. Histologic type squamous cell carcinoma, conventional (keratinizing).
- Histologic grade 2, moderately differentiated. Tumor extends into the paraglottic space. Lymph-vascular space not identified.
- **Perineural invasion present.** Surgical margins negative, closest margin is the radial margin greater than 9 mm.
- All regional lymph nodes negative for tumor (75).

Pathologic stage T3 N0.




40

NCCN Guidelines for Recurrent Head and Neck Cancers

Surgical resection is recommended primary treatment for locoregional reoccurrence with prior XRT

T3 N0 M0 disease.

- Reirradiation should be used in a highly select subset of patients due to risk of irreversible toxicities.
- Weekly Carboplatin or Cisplatin with concurrent XRT may also be considered.
- Research trials should be considered when reirradiation is not recommended.



41

Case Study #3: Adjuvant Course


3/14/25: Follow-up H&N MDC Visit

- H&N Surgery follow-up
- RD follow-up: Cont G tube feeds, PO per SLP, aggressive replacement
- SLP follow-up: MBSS scheduled 3/19/25, TEP consult
- RN Navigator follow-up: Coordination of care

3/19/25: Follow-up H&N MDC Visit

- H&N Surgery follow-up
- Radiation Oncology follow-up: rec consolidative re-RT 2/2 +PNI
- Behavioral Oncology follow-up
- SLP follow-up: post-MBSS review
- RD follow-up: cont G tube feeds, PO per SLP, aggressive replacement
- RN Navigator follow-up: coordination of care

Tx ongoing.




42

Case Study #3 Recurrent H & N Cancer Takeaways

Navigation Takeaways

- Delayed diagnosis, patient canceled multiple appointments
- H&N Nurse Navigator provided support for both patient and caregiver
- Free flap surgery with aggressive prehabilitation and rehabilitation support
- Multidisciplinary review proved critical in determining the best treatment recommendations for the patient. I.e., plan for salvage surgery vs re-irradiation following DLE with biopsy proven recurrence.




43

Barriers to care

Patient Related:

- Rural locations lack cancer treatment centers and supportive care, i.e.:
 - Dental surgeon
 - SLP
 - OT
 - PET
- Behaviors/Choices
- Lack of follow up with recommendations




44

Social Determinants of Health



<https://www.cdc.gov/nceh/field/docs/2014/04/social-determinants-of-health/>




45


Barriers to Care Cont.

Provider Related:

- Lack multidisciplinary clinic for H&N cancer
- Communication challenges
- Care not well coordinated
- Education; not providing information in ways patients can understand
- Mental health and emotional concerns are not addressed




Stock photo



46

Barriers to Care Cont.

- System Related:
 - Multiple EMRs
 - Various sites where care is provided
 - Inadequate health insurance coverage
 - Lack of dental insurance
 - Travel logistics to various sites in and out of area
- Optimal Care:
 - High volume centers
 - Dedicated H&N RN navigators
 - Multidisciplinary meetings for care coordination




Stock Photo

• [Amoroso.org](#). Accessed February 10, 2025. From 204-010-247-001 ASCO Meeting Abstracts from the 2024 ASCO annual meeting. Studying perceived barriers to optimal care in head and neck cancer: A mixed-methods study. Powell, P. et al.

• [Powell et al. Evaluating perceived barriers to optimal care in head and neck cancer: A mixed-methods study. JCO 44: 6079-6079\(2025\)](#)

• [doi:10.1200/JCO.2024.44.6079-6079](#)



47

Supportive Resources in Survivorship

Psychosocial

- Support Groups
 - SPOHNC.org
 - WebWhispers.org

Counseling/Therapy


- Psychologytoday.com
- PCP
- LCSW

Organizations

- Head and Neck Cancer Alliance
- American Cancer Society
- The Laryngectomy Site

Providers

- Oncologists
- Pain Specialists
- RD
- SLP, OT
- Survivorship Plan APP
- RN Navigator



48

QUESTION & ANSWER

Interprofessional Insights:
Advanced Care Coordination for Patients with
Head and Neck Cancer

Jennifer Lewellyn, RN, OCN
Head and Neck Nurse Navigator

Jaclyn V. Moore, MS, RD, C.S.O.
Oncology Dietitian

Transforming Oncology Care Through Medically Integrated Collaboration

2024 NCODA
SPRING
FORUM

49

CE CODES

Interprofessional Insights:
Advanced Care Coordination for Patients with
Head and Neck Cancer

Transforming Oncology Care Through Medically Integrated Collaboration

2024 NCODA
SPRING
FORUM

50
